In addition, as emerged from the Bosentan Use in Interstitial Lung Disease (BUILD)-3 trial, baseline levels of MMP-7 were the only reliable predictor of lung function decline and IPF progression [64]. This evidence concerns the gene MMP7 and idiopathic pulmonary fibrosis.